Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test: MIP: ProteoMediX AG

• Unité de recherche: INNOSUISSE
• Numéro de projet: 16771.3 PFLS-LS
• Titre du projet anglais: Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test: MIP: ProteoMediX AG

Description succincte (Allemand)

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test

Description succincte (Anglais)

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test: MIP: ProteoMediX AG

Résumé des résultats (Abstract) (Allemand)

The goal of the interdisciplinary ProteoMediX/ETHZ/USZ/FHNW project is to develop an immunoassay-based risk stratification test (PMX-Px) for the prognosis of patients diagnosed|with localized prostate cancer (PCa) by using Mass Spectrometry-GUided Immunoassay DEvelopment (MS-GUIDE). A commercially available kit in the context of personalized|medicine will provide doctors and patients with a tool supporting them in their decision making in between prostatectomy or active surveillance for patients with localized|PCa.

Résumé des résultats (Abstract) (Anglais)

The goal of the interdisciplinary ProteoMediX/ETHZ/USZ/FHNW project is to develop an immunoassay-based risk stratification test (PMX-Px) for the prognosis of patients diagnosed|with localized prostate cancer (PCa) by using Mass Spectrometry-GUided Immunoassay DEvelopment (MS-GUIDE). A commercially available kit in the context of personalized|medicine will provide doctors and patients with a tool supporting them in their decision making in between prostatectomy or active surveillance for patients with localized|PCa.